|
Beurs gesloten -
Nasdaq
22:00:00 18-02-2026
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
|
332,68 USD
|
+0,02%
|
 |
+3,23%
|
-16,34%
|
| 10:22 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,284,980, According to a Recent SEC Filing
| | | 10:20 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $607,448, According to a Recent SEC Filing
| | | 10:20 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $2,157,542, According to a Recent SEC Filing
| | | 10:19 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $695,201, According to a Recent SEC Filing
| | |
17/02 |
Die große KI-Neubewertung
| | |
17/02 |
Analyst recommendations: Accenture, Dollar Tree, DraftKings, Moderna, Walmart…
| | |
12/02 |
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
| | |
12/02 |
Sector Update: Health Care Stocks Fall Pre-Bell Thursday
| | |
12/02 |
Alnylam Pharmaceuticals : Q4 2025 Earnings Presentation ›
| | |
12/02 |
Alnylam Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Issues 2026 Outlook
| | |
12/02 |
Alnylam: Q4 Earnings Snapshot
| | |
12/02 |
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $1.25 per Share
| | |
12/02 |
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q4 Revenue $1.10B, vs. FactSet Est of $1.15B
| | |
12/02 |
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
| | |
11/02 |
Pharma companies left out of Trump's drug-pricing deals look for way in
| | |
29/01 |
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
| | |
27/01 |
Intellia gets FDA nod to resume one gene therapy trial after safety pause
| | |
14/01 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,395,992, According to a Recent SEC Filing
| | |
14/01 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $547,927, According to a Recent SEC Filing
| | |
14/01 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,008,766, According to a Recent SEC Filing
| | |
14/01 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,475,157, According to a Recent SEC Filing
| | |
14/01 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $547,929, According to a Recent SEC Filing
| | |
13/01 |
Alnylam Pharmaceuticals CEO on Development Goals, Profitability
| | |
12/01 |
Alnylam Pharmaceuticals : 2026 J.P. Morgan Presentation
| | |
11/01 |
Alnylam Pharmaceuticals : Launches “ 2030” Strategy to Drive Next Era of Growth and Patient Impact
| |
Geen resultaten voor deze zoekopdracht Kies jouw editie Alle financiële informatie op nationaal niveau
MarketScreener is also available in this country: United States.
Switch edition
Ik blijf hier.
| 
